It is recommended that you also refer to http://www.medicines.ie as the Summary of Product Characteristics may have been updated since this copy was printed.

Recordati Ireland Limited

Recordati Ireland Limited

Summary of Product Characteristics last updated on medicines.ie: 30/5/2016

Phospho-soda 24.4g / 10.8g oral solution

1. NAME OF THE MEDICINAL PRODUCT

Phospho-soda 24.4g / 10.8g oral solution

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

per 45ml dose

per 1ml

Sodium dihydrogen phosphate dihydrate

24.4 g

0.542 g

Disodium phosphate dodecahydrate

10.8 g

0.24 g

Each 45ml bottle contains 5.0 g sodium.

Excipient(s) with known effect: Phospho-soda contains a very small amount of ethanol, less than 100 mg per dose.

For the full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

Oral solution.

Clear colourless solution with a ginger-lemon odour, free from precipitation and turbidity.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

As a bowel cleanser in preparing the patient for colon surgery, or for preparing the colon for x-ray or for endoscopic examination.

Bowel cleansing agents are not to be considered as treatments for constipation.

Phospho-soda is indicated in adults.

4.2 Posology and method of administration

Posology

Adults Only: Not to be given to children under the age of 18 years.

Elderly patients: As for Adults.

Method of administration

The taking of Phospho-soda should be started the day before the hospital appointment.

For hospital appointments before 12 noon the dosage instructions for morning appointments should be followed and for appointments after 12 noon the dosage instructions for an afternoon appointment should be followed.

MORNING APPOINTMENT:

Day before appointment

7am – In place of breakfast drink at least one full glass of “clear liquid” or water, more if desired.

“Clear liquids” includes water, clear soup, strained fruit juices without pulp, black tea or black coffee, clear carbonated and non-carbonated soft drinks.

1st Dose  – Straight afterwards, dilute 45ml in half a glass (120ml) cold water. Drink this solution followed by one full glass (240ml) cold water, more if desired.

Drink as much extra liquids as possible to replace the fluids lost during bowel movements.

1pm lunch – In place of lunch drink at least three full glasses (720ml) of “clear liquid” or water, more if desired.

7pm supper – In place of supper drink at least one full glass of “clear liquid” or water, more if desired.

2nd Dose  – Straight afterwards, dilute 45ml in half a glass (120ml) cold water. Drink this solution followed by one full glass (240ml) cold water, more if desired.

Additional water or “clear liquids” may be taken up until midnight if necessary.

Drinking large amounts of clear liquid also helps ensure that the bowel will be clean for the procedure.

AFTERNOON APPOINTMENT:

Day before appointment

1pm lunch – A light snack may be taken. After lunch, no more solid food must be taken until after the hospital appointment.

7pm supper – In place of supper drink at least one full glass of “clear liquid” or water, more if desired.

1st Dose  – Straight afterwards, dilute 45ml in half a glass (120ml) cold water. Drink this solution followed by one full glass (240ml) cold water, more if desired.

Drink as much extra liquid as possible to replace the fluids lost during bowel movements.

During the evening, drink at least three full glasses of water or “clear liquid” before going to bed.

Day of appointment

7am breakfast – In place of breakfast drink at least one full glass of “clear liquid” or water, more if desired.

2nd Dose  – Straight afterwards, dilute 45ml in half a glass (120ml) cold water. Drink this solution followed by one full glass (240ml) cold water.

Drink as much extra liquid as possible to replace the fluids lost during bowel movements. Drinking large amounts of clear liquids also helps ensure that the bowel will be clean for the procedure.

More water or “clear liquid” may be taken up until 8am.

This product normally produces a bowel movement in ½ to 6 hours.

After the procedure:

In order to replace fluid lost during the preparation for the procedure patients should be encouraged to drink plenty of fluids afterwards.

4.3 Contraindications

Do not use:

• In children under the age of 18 years.

• When nausea, vomiting or abdominal pain are present.

• There is hypersensitivity to the active substances or to any of the excipients listed in section 6.1

Do not use in patients with:

• Clinically significant impairment of renal function;

• Primary hyperparathyroidism associated with hypercalcaemia

• Congestive heart failure;

• Ascites;

• Known or suspected gastrointestinal obstruction;

• Megacolon (congenital or acquired);

• Perforation;

• Ileus;

• Active inflammatory bowel disease.

Phospho-soda should not be used in combination with other laxative products containing sodium phosphate.

4.4 Special warnings and precautions for use

Phospho-soda® has been rarely associated with severe and potentially fatal cases of electrolyte disorders in elderly patients. The benefit/risk ratio of Phospho-soda® needs to be carefully considered before initiating treatment in this at-risk population.

Special attention should be taken when prescribing Phospho-soda® to any patient with regard to known contraindications and the importance of adequate hydration and, in at-risk populations (see below and sections 4.2 and 4.3.), the importance of also obtaining baseline and post-treatment electrolyte levels.

Dehydration

This product usually works within ½ to 6 hours. If there has been no bowel movement within 6 hours of taking Phospho-soda, instruct the patient to stop use and contact a doctor immediately as dehydration could occur.

Patients should be warned to expect frequent, liquid stools. Patients should be encouraged to drink as much liquid as possible to help prevent dehydration. Inadequate fluid intake when using any effective purgative may lead to excessive fluid loss possibly producing dehydration and hypovolemia. Dehydration and hypovolemia from purgation may be exacerbated by inadequate oral fluid intake, nausea, vomiting, loss of appetite, or use of diuretics, angiotensin converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBS), and non-steroidal anti-inflammatory drugs (NSAIDs) and may be associated with acute renal failure. There have been rare reports of acute renal failure with purgatives, including sodium phosphates and PEG-3350.

Patients with conditions that may predispose to dehydration or those taking medications which may decrease glomerular filtration rate, should be assessed for hydration status prior to use of purgative preparations and managed appropriately.

Nephrocalcinosis

Nephrocalcinosis associated with acute renal failure and deposits of calcium-phosphate crystals in the renal tubules has been rarely reported in patients using sodium phosphates for bowel cleansing; Nephrocalcinosis is a serious adverse event that may result in permanent renal function impairment and the requirement of long-term dialysis. The majority of these reports occurred in elderly female patients taking drugs to treat hypertension or other drug products, such as diuretics or NSAIDs, that may result in dehydration.

Care should be taken to prescribe Phospho-soda per recommendations with a particular attention to known contraindications and adequate hydration.

At risk patients

Use with caution in patients with an increased risk for underlying renal impairment, pre-existing electrolyte disturbances, increased risk for electrolyte disturbances (e.g. dehydration, gastric retention, colitis, inability to take adequate oral fluid, hypertension or other conditions in which the patients are taking products that may result in dehydration, see below), hypotension with clinical impact or associated with hypovolaemia, , heart disease, acute myocardial infarction, unstable angina, , or with debilitated or elderly patients. In these at-risk patients, consider obtaining baseline and post-treatment sodium, potassium, calcium, chloride, bicarbonate, phosphate, blood urea nitrogen and creatinine values.

Electrolyte disorders

There is a risk of elevated serum levels of sodium and phosphate and decreased levels of calcium and potassium; consequently hypernatraemia, hyperphosphataemia, hypocalcaemia, hypokalaemia, and acidosis may occur.

Slight QT interval prolongation may rarely occur as a result of electrolyte imbalances such as hypocalcaemia or hypokalaemia. These changes are clinically insignificant.

Hypomotility

Use with caution in patients with hypomotility disorders or who have had gastro-intestinal surgery or have other medical conditions predisposing them to hypomotility disorders. If the patient has had a colostomy or ileostomy, or must keep to a salt-free diet, the preparation must be used with caution, since a disturbance of electrolyte balance, dehydration or a disturbance of acid balance may arise.

Lesions

Single or multiple aphthoid-like punctiform lesions located in the rectosigmoid region have been observed by endoscopy. These were either lymphoid follicles or discrete inflammatory infiltrates or epithelial congestions/changes revealed by the colonic preparation. These abnormalities are not clinically significant and disappear spontaneously without any treatment.

Sodium content

Phospho-soda contains 5.0g sodium in each 45 ml dose. Consideration should therefore be given to the potential harm to patients requiring a low-sodium diet.

4.5 Interaction with other medicinal products and other forms of interaction

Use with caution in patients taking calcium channel blockers, diuretics, lithium treatment or other medications that might affect electrolyte levels as hyperphosphataemia, hypocalcaemia, hypokalaemia, hypernatraemic dehydration and acidosis may occur.

During the intake of Phospho-soda the absorption of drugs from the gastrointestinal tract may be delayed or even completely prevented. The efficacy of regularly taken oral drugs (e.g. oral contraceptives, antiepileptic drugs, antidiabetics, antibiotics) may be reduced or completely absent. Caution is also advised when taking medicines known to prolong the QT interval.

Use with caution in patients who are taking parathyroid hormone medications.

4.6 Fertility, pregnancy and lactation

Pregnancy

For Phospho-soda, no clinical data on exposed pregnancies and no data from animal studies with respect to effects on pregnancy, embryonal/fetal development, parturition and postnatal development are available. The potential risk for humans is unknown. Phospho-soda should not be used during pregnancy unless clearly necessary.

Breastfeeding

It is not known whether Phospho-soda is excreted in human milk. As sodium phosphate may pass into the breast milk, it is advised that breast milk is expressed and discarded from the first dose to 24 hours after the second dose of the bowel cleansing solution. Women should not breast-feed their infants until 24 hours after receiving the second dose of Phospho-soda.

4.7 Effects on ability to drive and use machines

Phospho-Soda may cause dizziness, probably as a result of dehydration.

Phospho-Soda has minor to moderate influence on the ability to drive and use machines.

4.8 Undesirable effects

The following adverse reactions were reported with frequencies corresponding to: Very common (≥1/10), Common (≥ 1/100, < 1/10), Uncommon (≥ 1/1,000, < 1/100), Rare (≥1/10,000, < 1/1,000), Very rare (≤ 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

IMMUNE SYSTEM DISORDERS

Very rare

Hypersensitivity

METABOLISM AND NUTRITION DISORDERS

Uncommon

Dehydration

Very rare

Hyperphosphataemia

Hypocalcaemia

Hypokalaemia

Hypernatraemia

Metabolic acidosis

Tetany

NERVOUS SYSTEM DISORDERS

Very common

Dizziness

Common

Headache

Very rare

Loss of consciousness

Paraesthesia

CARDIAC DISORDERS

Very rare

Myocardial infarction

Arrhythmia

VASCULAR DISORDERS

Very rare

Hypotension

GASTROINTESTINAL DISORDERS

Very common

Diarrhoea

Abdominal pain

Abdominal distension

Nausea

Common

Vomiting

Colonoscopia abnormal (Single or multiple aphthoid-like punctiform lesions located in the rectosigmoid region that are not clinically significant and disappear spontaneously without any treatment)

SKIN AND SUBCUTANEOUS TISSUE DISORDERS

Very rare

Dermatitis allergic

MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS

Very rare

Muscle cramp

RENAL AND URINARY DISORDERS

Rare

Nephrocalcinosis

Very rare

Renal failure acute

Renal failure chronic

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS

Very common

Chills

Asthenia

Common

Chest pain

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL-Dublin 2; Tel: +353 1 6764971; Fax: + 353 1 6762517 Website: www.hpra.ie Email: medsafety@hpra.ie

4.9 Overdose

There have been fatal cases of hyperphosphataemia with concomitant hypocalcaemia, hypernatraemia and acidosis when Phospho-soda has been used in excessive doses, given to children or to obstructed patients.

Patients experiencing overdose have presented the following symptoms: dehydration, hypotension, tachycardia, bradycardia, tachypnoea, cardiac arrest, shock, respiratory failure, dyspnoea, convulsions, ileus paralytic, anxiety, pain. Overdoses can lead to elevated serum levels of sodium and phosphate and decreased levels of calcium and potassium. In those cases, hypernatremia, hyperphosphatemia, hypocalcemia, hypokalemia, and acidosis may occur.

There are also documented cases of complete recovery from overdoses in both children accidentally given Phospho-soda, and also in patients with obstruction, one of whom received a six-fold overdose.

Recovery from the toxic effect of excess ingestion can normally be achieved by rehydration, though the intravenous administration of 10% calcium gluconate may be necessary.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Osmotically acting laxative, ATC code: A06AD17

Phospho-soda is a saline laxative that acts by osmotic processes to increase fluid retention in the lumen of the small intestine. Fluid accumulation in the ileum produces distension and, in turn, promotes peristalsis and bowel evacuation.

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

No animal studies on reproduction toxicity have been conducted with Phospho-soda.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Glycerol

Saccharin Sodium

Sodium Benzoate (E211)

Ginger Lemon Flavour*

Purified Water

*Ginger Lemon Flavour:

Oleoresin Ginger

Alcohol

Oil Lemon

Partially Deterpinated Oil Lemon

Citric Acid

Water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

Once opened, use immediately. Discard any unused portion.

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

Phospho-soda is supplied in cartons containing 2 x 45ml or 100 x 45ml (hospital pack) polyethylene bottles with polypropylene, aluminium foil-lined screw caps.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

This product must be diluted with water before use.

7. MARKETING AUTHORISATION HOLDER

Casen Recordati S.L.

Autovía de Logroño, Km. 13,300

50180 UTEBO. Zaragoza (Spain)

8. MARKETING AUTHORISATION NUMBER(S)

PA 2028/004/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 06 July 1998

Date of latest renewal: 30 April 2010

10. DATE OF REVISION OF THE TEXT

April 2016

It is recommended that you also refer to http://www.medicines.ie as the Summary of Product Characteristics may have been updated since this copy was printed.